Sign In
Buy AEMD
$1.36
-0.0200 (-1.45%)
At Close: Jun 23, 2026
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
08:01am, Tuesday, 08'th Oct 2024
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases,
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
10:00am, Thursday, 19'th Sep 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and dev
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
08:01am, Thursday, 19'th Sep 2024
Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumor
Aethlon Medical to Present at Virtual Investor Conferences in September
08:01am, Tuesday, 17'th Sep 2024
SAN DIEGO , Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases
Innovation Driving Cancer's Solid Tumors Market
07:30am, Tuesday, 17'th Sep 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and deve
Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- A
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
08:35am, Friday, 13'th Sep 2024
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as
Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ --
Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript
06:45pm, Wednesday, 14'th Aug 2024
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2025 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chie
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
04:15pm, Wednesday, 14'th Aug 2024
Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; E
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
09:01am, Monday, 12'th Aug 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent
Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
08:01am, Monday, 12'th Aug 2024
Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with So
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
09:12am, Tuesday, 06'th Aug 2024
SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, t
Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript
06:37pm, Thursday, 27'th Jun 2024
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaR
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
04:15pm, Thursday, 27'th Jun 2024
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat
